Cybin Inc. CYBN Archives - Page 13 of 18

MondayNov 15, 2021 11:02 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Q2 Financial Results, Business Highlights

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has released its unaudited second-quarter results and announced a conference call to review the report. The report covers the period ended Sept. 30, 2021. Highlights in the report included the company’s announcement of preclinical data for its novel deuterated psilocybin analog, CYB003, for the potential treatment of major depressive disorder and alcohol use disorder. The company has also been granted a Schedule I manufacturing license from the U.S. Drug Enforcement Agency for its Boston-area research lab and has received FDA approval to proceed with a company-sponsored…

ThursdayNov 11, 2021 12:29 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Launches Transformative Training Program for Psychedelic Facilitatorswddd

The EMBARK program represents the broad spectrum of ways in which therapeutic benefits might be experienced Program offers psychedelic clinical trial facilitators foundational training to provide skillful, ethical care to participants receiving psychedelic treatment EMBARK is built around open architecture to support varieties of psychedelic experience within a coherent therapeutic framework In a climate where psychedelic treatments are increasing in usage and acceptance, the importance of providing support and guidance in the space becomes even more important. With that in mind, Cybin (NEO: CYBN) (NYSE American: CYBN) has launched its proprietary EMBARK Psychedelic Facilitator Training Program (https://ibn.fm/3lzkp). Named for the program’s…

ThursdayNov 11, 2021 11:08 am

QualityStocksNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at Jefferies London Healthcare Conference

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” has announced that its CEO Doug Drysdale will present at the Jefferies London Healthcare Conference. The event is slated to be held in a virtual format from Nov. 18-19, 2021. Drysdale’s presentation will be available on demand beginning at 8:00 a.m. GMT on Thursday, Nov. 18 through 5:00 p.m. GMT on Friday, Nov. 19. Interested parties should visit https://ibn.fm/LREaZ to register for the webcast and view the presentation. An archived webcast will be available on the company’s investor relations website. To view the full press release, visit https://ibn.fm/Xhp0W…

TuesdayNov 09, 2021 10:37 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Release Q2 2021 Financial Results, Host Call

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing Psychedelics to Therapeutics(TM), is planning to release its Q2 2021 financial report on Nov. 15, 2021. The report will cover the period ended Sept. 30, 2021. The company is also planning on hosting a conference call and webcast the same day, which is scheduled to begin at 4:30 p.m. EST. The call will be hosted by Cybin CEO Doug Drysdale and will provide an overview of the financial results along with relevant business updates. In addition, Drysdale and other team members will answer questions during the call. Those who…

MondayNov 08, 2021 10:59 am

QualityStocksNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) CYB003 Demonstrates Numerous Advantages over Oral Psilocybin for Treatment of Mental Health

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced positive CYB003 pre-clinical findings. According to the update, the findings demonstrate multiple advantages for Cybin’s newly developed novel deuterated psilocybin analog over oral psilocybin for the treatment of mental health. “Multiple academic studies have shown that psilocybin may have the potential to revolutionize mental health care, but few companies have addressed the well-known limitations and side effects of oral psilocybin,” said Cybin’s CEO Doug Drysdale in the news release. “Cybin has always strived to develop safer and more effective therapies for patients, which…

ThursdayNov 04, 2021 10:55 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Schedule I Manufacturing License from DEA

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics(TM), has been granted a Schedule I manufacturing license from the U.S. Drug Enforcement Agency (“DEA”). Granted for Cybin’s research lab located in the Boston area, the license is required for investigators who plan to study, produce, analyze or otherwise work with Schedule I controlled substances. According to the announcement, the company is working to become a hub for innovation and drug discovery. Cybin has relied on in-house capabilities as well as globally licensed research organizations in the United States, Canada and the United Kingdom for most…

TuesdayNov 02, 2021 10:32 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Schedules R&D Briefing to Release Breakthrough Research Findings

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, will be hosting an in-person and virtual research and development briefing. Scheduled for Nov. 8, 2021, from 8:30–9:30 a.m. EST, the briefing is slated to include breakthrough preclinical, research findings that indicate advancements in the company’s focus on creating a promising approach for patients in need of effective and safe prescription therapies in the mental health space. Cybin CEO Doug Drysdale and other key members of the company’s senior scientific research team will be hosting the event, which will be held during the Wonderland Conference in Miami;…

ThursdayOct 28, 2021 11:05 am

QualityStocksNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Unveils Psychedelic Facilitator Training Program Based on Groundbreaking Psychotherapy Approach

Cybin (NYSE American: CYBN) (NEO: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, is launching its own psychedelic facilitator training program. Called EMBARK, the project is led by expert faculty and provides psychedelic clinical trial facilitators with fundamental training to provide skillful, ethical care to individuals receiving psychedelic treatment. EMBARK emphasizes experiential learning and includes an in-person training retreat at the Whidbey Institute, a home for transformational learning in Washington state as well the training and practice sessions on the EMBARK model, a groundbreaking psychotherapy approach that incorporates psychedelic medicine with leading clinical approaches designed to promote supportive healing.…

TuesdayOct 26, 2021 1:28 pm

QualityStocksNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces FDA IND Authorization of Potentially Pivotal Study

Cybin (NYSE American: CYBN) (NEO: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has announced that the U.S. Food and Drug Administration (“FDA”) has authorized an Investigational New Drug (“IND”) application to proceed with the company’s sponsored feasibility study. The study focuses on using Kernel’s Flow technology to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics. “The word psychedelic means ‘mind-manifesting,’ but what has been missing is useful ‘mind-imaging’—the ability to dynamically trace the neural correlates of human conscious experience,” said Cybin’s Chief Clinical Officer Dr. Alex Belser. “Conventional neuroimaging just isn’t dynamic enough to study the psychedelic experience…

WednesdayOct 20, 2021 1:38 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Files Patent Application Amid ‘New Era’ of Psychedelic Medicine

Substances such as psilocybin, ketamine and LSD are edging into mainstream culture, setting the stage for a paradigm shift in modern medicine Cybin has filed an international patent application covering methods for the delivery of psychedelic medications by inhalation The company is pursuing the effectiveness of using inhalation as a delivery method for psychedelic medications Earlier this month, a Time magazine article reported on the “new era” of psychedelic medicine (https://ibn.fm/bfC3u). On the leading edge of this collective breakthrough is Cybin (NEO: CYBN) (NYSE American: CYBN), a company focused on progressing psychedelic therapeutics, addressing the mental health crisis and transforming the…

Site Search

Company Search

Tag: Cybin Inc. CYBN